PHF2

Lysine-specific demethylase PHF2 · O75151 · PHF2 on Sugi Atlas →

477 patent compounds predicted against PHF2, 447 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Amiodarone (SCHEMBL16284)	1.00	1/20
Amiodarone (SCHEMBL5496372)	1.00	1/20
Amiodarone (SCHEMBL12487240)	1.00	1/20
Amiodarone (SCHEMBL29361787)	1.00	1/20
Amiodarone (SCHEMBL41348)	0.98	1/20
Amiodarone (SCHEMBL28525007)	0.98	1/20
Amiodarone (SCHEMBL29173757)	0.98	1/20
Amiodarone (SCHEMBL29183902)	0.98	1/20
Amiodarone (SCHEMBL29362650)	0.98	1/20
Amiodarone (SCHEMBL1648547)	0.96	1/20
Amiodarone (SCHEMBL19809514)	0.96	1/20
Amiodarone (SCHEMBL28184969)	0.96	1/20
Amiodarone (SCHEMBL28989964)	0.96	1/20
Amiodarone (SCHEMBL5034221)	0.95	1/20
Amiodarone (SCHEMBL8002330)	0.91	1/20
SCHEMBL8487560	0.91	1/20
SCHEMBL15314912	0.90	1/20
SCHEMBL18500883	0.89	1/20
Amiodarone (SCHEMBL28794251)	0.88	1/20
SCHEMBL15314927	0.88	1/20

Clinical trials — most relevant to PHF2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)	PHASE1	NOT_YET_RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Safety and Pharmacokinetic Profile of CKD-581	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19	nan	COMPLETED
The Molecular Pathogenesis Study of Cataract	nan	UNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED
Mechanisms of Immune Deficiency	nan	UNKNOWN
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins	nan	COMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Using the Epitranscriptome to Diagnose and Treat Gliomas	nan	RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors	nan	UNKNOWN
COPENHAGEN Minipuberty Study	nan	UNKNOWN
Detection of IKZF1 Deletion Mutation in Patients With Acute Lymphoblastic Leukemia and Its Impact in Therapy	nan	UNKNOWN
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells.	nan	UNKNOWN
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PHF2 binder may also engage these)

Protein	Name	Similarity
Q9WTU0	—	1.000	Q9WTU0 →
Q80TJ7	—	0.995	Q80TJ7 →
P0CH95	—	0.992	P0CH95 →
Q6P949	—	0.991	Q6P949 →
E6ZGB4	—	0.991	E6ZGB4 →
PHF8	Histone lysine demethylase PHF8	0.991	landscape →
Q3UWM4	—	0.988	Q3UWM4 →
P49140	—	0.988	P49140 →
Q62315	—	0.988	Q62315 →
Q5RHD1	—	0.987	Q5RHD1 →
Q08D35	—	0.987	Q08D35 →
KDM7A	Lysine-specific demethylase 7A	0.986	landscape →
Q92833	—	0.986	Q92833 →
Q5XJV7	—	0.985	Q5XJV7 →
Q4V7W5	—	0.984	Q4V7W5 →
Q02225	—	0.983	Q02225 →
Q5F363	—	0.983	Q5F363 →
Q8K2L8	—	0.983	Q8K2L8 →
Q08BR4	—	0.983	Q08BR4 →
Q9H694	—	0.983	Q9H694 →
O88974	—	0.983	O88974 →
KAT2B	Histone acetyltransferase KAT2B	0.983	landscape →
E1BTG2	—	0.983	E1BTG2 →
Q5R6Y9	—	0.982	Q5R6Y9 →
Q8N5Y2	—	0.982	Q8N5Y2 →
SETDB1	Histone-lysine N-methyltransferase SETDB1	0.982	landscape →
P78524	—	0.982	P78524 →
Q62925	—	0.982	Q62925 →
Q09YG9	—	0.981	Q09YG9 →
Q3UQU0	—	0.981	Q3UQU0 →